ARCHIVES

FDA Backs Down, Releases INDs, But Revives Controversy Over Clinical Testing Guidelines

This article is from The Cancer Letter archive.

Vol. 02 No. 11 | March 12, 1976

Download PDF Visit The Full Archive

Related Articles

In Brief: ACS to Spend Record $85 Million On Research: AACR To Honor Hanafusa, DeVita, Barbacid

March 14, 1986

Cancer Program Critics Called “Irresponsible,” Demagogues”

March 21, 1975

High Dose Chemotherapy Significantly Prolongs Survival In ECOG Clinical Trial

November 28, 2008

NCAB Opposes Line Item for Centers

May 23, 1980

FDA Warns of Lymphoma Risk Associated With Breast Implants

January 28, 2011

ORI Finds Misconduct By Two Researchers

December 8, 1995